Abstract
3P AZ12756122, a novel fatty acid synthase (FASN) inhibitor, reduces resistance properties in gefitinib- and osimertinib-resistant EGFR-mutated non-small cell lung cancer models
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have